Table 1. Demographic and disease characteristics.
| Characteristic | Platinum-sensitive (N=171) | Platinum-resistant (N=49) | Total (N=220) |
|---|---|---|---|
| Median age (range), years | 69 (37–93) | 66 (25–83) | 68 (25–93) |
| Median time since diagnosis (range), months | 32.2 (10.2–285.2) | 24.4 (7.6–184.2) | 30.6 (7.6–285.2) |
| Germline BRCA1/2 mutation, N (%)a | |||
| BRCA1 | 11 (6.4) | 3 (6.1) | 14 (6.4) |
| BRCA2 | 7 (4.1) | 5 (10.2) | 12 (5.5) |
| Histology, N (%) | |||
| High-grade serous | 160 (93.6) | 49 (100) | 209 (95.0) |
| G3 Endometrioid | 5 (2.9) | 0 | 5 (2.3) |
| Carcinosarcoma | 1 (0.6) | 0 | 1 (0.4) |
| Missing | 5 (2.9) | 0 | 5 (2.3) |
| Number of prior treatment regimens | |||
| Median number of regimens (range) | 1 (1–5) | 2 (1–12) | 1 (1–12) |
| 1, N (%) | 120 (70.2) | 17 (34.7) | 137 (62.3) |
| 2, N (%) | 39 (22.8) | 23 (46.9) | 62 (28.2) |
| 3, N (%) | 6 (3.5) | 1 (2.0) | 7 (3.2) |
| 4, N (%) | 1 (0.6) | 2 (4.1) | 3 (1.4) |
| >4, N (%) | 3 (1.7) | 6 (12.3) | 9 (4.0) |
| Data missing | 2 (1.2) | 0 | 2 (0.9) |
a
Mutation status as recorded at time of study entry.